AstraZeneca
AZN Big PharmaAnglo-Swedish pharma with strength in oncology, cardiovascular, and respiratory. Key drugs include Tagrisso, Farxiga, and Imfinzi. COVID-19 vaccine partner with Oxford.
FDA Novel Drug Designations
(2017-2023)AstraZeneca at a Glance
- Leading 23 drug targets across portfolio
- Fast trial execution (10 months median completion)
AstraZeneca's Key Drugs
AstraZeneca's core commercial portfolio centers on TAGRISSO, FARXIGA, IMFINZI, spanning Oncology and Respiratory — its most strategically important drugs approved in the last 15 years.
Adjuvant therapy after tumor resection in adult patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive non-small cell lung cancer (NSCLC)
Chronic Kidney Disease
Non-Small Cell Lung Cancer
Previously untreated mantle cell lymphoma in patients ineligible for autologous hematopoietic stem cell transplantation (in combination with bendamustine and rituximab)
Hay Fever
AstraZeneca News
All AstraZeneca news →- Oct 30, 2026 EarningsAstraZeneca results: 9M and Q3 2026 Continued strong commercial performance and 12 positive Phase III programme readouts in the year to dat e ↗
- Oct 27, 2026 RegulatoryEnhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer ↗
- Oct 25, 2026 TrialsTagrisso plus Orpathys reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on Tagrisso ↗
- Oct 25, 2026 TrialsSonesitatug vedotin reduced the risk of death by 42% in 2nd- and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01 ↗
- Oct 24, 2026 TrialsPerioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer ↗
AstraZeneca's Recent FDA Approvals
AstraZeneca secured 5 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
AstraZeneca's Therapeutic Areas
AstraZeneca's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Respiratory, across 7 biologic and 29 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AstraZeneca's Top Competitors
AstraZeneca's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Boehringer Ingelheim. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AstraZeneca Pipeline Snapshot
AstraZeneca has 1143 active clinical programs from ClinicalTrials.gov — 376 Phase 3, 275 Phase 2 and 492 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 267/448 completed
- • Speed: 10 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (24)
Discontinued (7)
Company Info
- First Approval
- 1951-05-17
- Latest
- 2026-10-23
- Applications
- 109
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges